Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments

Waerzeggers, Yannic; Monfared, Parisa; Viel, Thomas; Faust, Andreas; Kopka, Klaus; Schäfers, Michael; Tavitian, Bertrand; Winkeler, Alexandra

doi:10.1259/bjr/66405626

Cited by 2 publications

(1 citation statement)

References 96 publications

(99 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the oncogenic transformation, the ECM ligand binding activity is regulated by changing various parameters, such as extracellular and intracellular ligands, e.g., the proteoglycan decorin or intracellular kindlins, as well as divalent cations and protons, redox-active compounds, and mechanical forces [ 82 , 100 , 101 , 102 , 103 , 104 , 105 ]. Therefore, integrin expression and surface abundance on cancer cells can serve as tumor (suppressor) markers, although this may vary between tumor entities [ 91 , 106 , 107 , 108 ]. For example, the expression of α3β1 and α11β1 integrins changes during CAF differentiation, whereupon CAFs interact via these integrins with ectopically expressed laminin-332 and desmoplastically abundant collagen, respectively, and thus support cancer cells [ 24 , 109 ].…”

Section: The “Give and Take” Between The Ecm And Cells Within The mentioning

confidence: 99%

Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment

Niland

Eble

2020

IJMS

View full text Add to dashboard Cite

The tumor microenvironment (TME) has become the focus of interest in cancer research and treatment. It includes the extracellular matrix (ECM) and ECM-modifying enzymes that are secreted by cancer and neighboring cells. The ECM serves both to anchor the tumor cells embedded in it and as a means of communication between the various cellular and non-cellular components of the TME. The cells of the TME modify their surrounding cancer-characteristic ECM. This in turn provides feedback to them via cellular receptors, thereby regulating, together with cytokines and exosomes, differentiation processes as well as tumor progression and spread. Matrix remodeling is accomplished by altering the repertoire of ECM components and by biophysical changes in stiffness and tension caused by ECM-crosslinking and ECM-degrading enzymes, in particular matrix metalloproteinases (MMPs). These can degrade ECM barriers or, by partial proteolysis, release soluble ECM fragments called matrikines, which influence cells inside and outside the TME. This review examines the changes in the ECM of the TME and the interaction between cells and the ECM, with a particular focus on MMPs.

show abstract

Section: The “Give and Take” Between The Ecm And Cells Within The mentioning

confidence: 99%

Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment

Niland

Eble

2020

IJMS

View full text Add to dashboard Cite

show abstract

Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies

Keunen

Taxt

Grüner

et al. 2014

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

The vast majority of malignant gliomas relapse after surgery and standard radio-chemotherapy. Novel molecular and cellular therapies are thus being developed, targeting specific aspects of tumor growth. While histopathology remains the gold standard for tumor classification, neuroimaging has over the years taken a central role in the diagnosis and treatment follow up of brain tumors. It is used to detect and localize lesions, define the target area for biopsies, plan surgical and radiation interventions and assess tumor progression and treatment outcome. In recent years the application of novel drugs including anti-angiogenic agents that affect the tumor vasculature, has drastically modulated the outcome of brain tumor imaging. To properly evaluate the effects of emerging experimental therapies and successfully support treatment decisions, neuroimaging will have to evolve. Multi-modal imaging systems with existing and new contrast agents, molecular tracers, technological advances and advanced data analysis can all contribute to the establishment of disease relevant biomarkers that will improve disease management and patient care. In this review, we address the challenges of glioma imaging in the context of novel molecular and cellular therapies, and take a prospective look at emerging experimental and pre-clinical imaging techniques that bear the promise of meeting these challenges.

show abstract

Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments

Cited by 2 publications

References 96 publications

Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment

Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment

Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies

Contact Info

Product

Resources

About